Multi-session fMRI-Neurofeedback in PTSD

Last updated: October 7, 2024
Sponsor: Andrew Nicholson
Overall Status: Active - Recruiting

Phase

N/A

Condition

Post-traumatic Stress Disorders

Treatment

MRI Biofeedback

Sham-MRI Biofeedback

Clinical Study ID

NCT05456958
ANicho01
  • Ages 18-65
  • All Genders

Study Summary

Post-traumatic stress disorder (PTSD) is a debilitating and highly prevalent psychiatric disorder that develops in the aftermath of trauma exposure (APA, 2013). PTSD has been strongly associated with altered activation patterns within several large-scale brain networks and, as such, it has been suggested that normalizing pathological brain activation may be an effective treatment approach.

The objective of this proposed study is to investigate the ability of PTSD patients to self-regulate aberrant neural circuitry associated with PTSD psychopathology using real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback. Here, the investigators are building upon previous single-session pilot studies examining the regulation of the amygdala and the posterior cingulate cortex (PCC) in PTSD (Nicholson et al., 2021) (Nicholson et al., 2016) by: (1) Examining the effect of multiple sessions of rt-fMRI neurofeedback and, (2) Comparing PCC- and amygdala-targeted rt-fMRI neurofeedback to sham-control groups with regards to changes in PTSD symptoms and neural connectivity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-65 years old

  • Fluent English speaker

  • Comfortable using electronic devices (i.e., laptop, tablet, smartphone, etc.)

  • Meet criteria for a primary diagnosis of PTSD via the DSM-5 on the ClinicianAdministered PTSD Scale (CAPS-5). Note: given high rates of PTSD co-morbidity withmajor depressive disorder and anxiety disorders, these participants will not beexcluded from the study, allowing for a naturalistic sample

  • Able to provide written informed consent.

Exclusion

Exclusion Criteria:

Medical

  • Pregnant women or women who are breastfeeding

  • Serious illness (including cardiac, hepatic, renal, respiratory, endocrinologic,neurologic, or hematologic disease) that is not stabilized based on the judgment ofprimary investigator

  • Contraindications for research MRI, including metallic implants

  • Neurological disease, past head injury with loss of consciousness, stroke, seizures

  • Major untreated medical illness (e.g., cancer, thyroid disorder)

  • Any other condition that might interfere with the person's capacity to give informedconsent, or to adhere to the study protocol.

Psychological/Psychiatric

  • Active substance use or abuse as defined by the MINI or judged to be a problem bythe PI

  • Current or past pain disorders, bipolar disorders or psychosis, schizophrenia, andany other psychotic disorder will be excluded

  • Participants will also be excluded for active suicidality, history of pervasivedevelopmental disorders, or any other major medical illnesses

  • Meeting criteria for substance use disorder in the past three months on the MINI

  • Chronic opioid analgesic use within the last three months

  • Any other condition that might interfere with the person's capacity to give informedconsent, or to adhere to the study protocol

  • Current engagement in a primary trauma-focused psychotherapy treatment.

Other

  • History of claustrophobia

  • Previous engagement in biofeedback, neurofeedback, or any form of brain stimulationtherapy.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: MRI Biofeedback
Phase:
Study Start date:
May 01, 2023
Estimated Completion Date:
September 30, 2025

Study Description

Overview of Study Procedure:

This study consists of the following components:

  1. Clinical assessment

  2. 5 x self-report symptom assessment battery that will be administered electronically via REDCap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases.

  3. 3 x rt-fMRI neurofeedback sessions, plus a 30-minute semi-structured qualitative interview immediately after the end of scanning with a trauma-informed and clinically trained graduate student

  4. 7 weeks of actigraphy device usage to monitor participant biological (sleep) rhythms and physical activity.

(1) Clinical Assessment: Those who meet criteria for inclusion will be scheduled for baseline clinical assessments. Baseline clinical assessments will include the Mini-International Neuropsychiatric Interview (MINI; (Sheehan et al., 1998), and the Clinician-Administered PTSD Scale-5 (CAPS-5; (Weathers et al., 2018). The MINI will be used to establish mental health disorder diagnoses, and the CAPS will be used to establish a primary diagnosis of PTSD and symptom severity. In keeping with previous single-session studies by our group (Nicholson et al., 2016; 2021), during the clinical assessment session PTSD participants will be asked to select personalized trauma-associated words that induce emotional responses as well as neutral words associated with neutrally salient memories. The chosen words will be utilized for the emotion induction paradigm during neurofeedback. To ensure that the words only induce moderate emotional arousal, participants will self-report levels of distress associated with viewing the words and selection will be limited to words with a maximum distress rating of 7/10.

(2) Self-report Assessments (via REDCap): In this study, participants will also complete a battery of self-report questionnaires prior to the first neurofeedback session, including: Life Events Checklist (LEC-5) (Weathers et al., 2013), Beck Depression Inventory (BDI) (Beck et al., 1997), Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 2003), Difficulties in Emotion Regulation Scale (DERS) (Perasso & Velotti, 2017), Multiscale Dissociation Inventory (MDI) (Briere et al., 2005), the Depression Anxiety Stress Scale-21 (DASS-21) (Lovibond & Lovibond, 1995), the Multidimensional Assessment of Interoceptive Awareness (MAIA) (Mehling et al., 2012), the Insomnia Severity Index (ISI) (Morin et al., 2011), and the PTSD Checklist for DSM-5 (PCL-5) (Blevins et al., 2015). The PCL-5, BDI, DERS, MDI, DASS-21, ISI, and MAIA will be completed again after each rt-fMRI session, as well as at a 1- month follow-up. This battery of questionnaires will be administered at each time interval via REDCap.

(3) rt-fMRI Neurofeedback Sessions: In this study, the investigators will employ a 3 arm (amygdala vs. PCC vs. sham-control) vs 3 session design. fMRI data will be acquired using a 3T whole-body MRI scanner at St. Joseph's Hospital, London, Ontario, which is associated with the University of Western Ontario. All participants will undergo 3 rt-fMRI training sessions over the course of a 3-week period (1 session per week). fMRI data will be acquired using a 3T whole-body MRI scanner (Magnetom Tim Trio, Siemens Medical Solutions, Erlangen, Germany), equipped with a 32-channel phased array head coil.

rt-fMRI sessions: At the start of each session and after each run within a session, participants will also be asked to measure their state PTSD and dissociative symptoms using the Response to Script-Driven Imagery Scale (RSDI). The RSDI is a brief, self-report, 7-item Likert scale (Hopper et al 2007) and will be administered to participants while they are inside the scanner. Each rt-fMRI session will proceed as follows: a pre-session RSDI, a localization scan, an anatomical scan, an initial resting-state scan, 4 task runs (~8 minutes per run; with an RSDI after each task run), followed by another resting-state scan. For each rt-fMRI session, there will be 3 training runs, followed by a transfer run (to assess neurofeedback learning effects), for a total of 4 task runs. The transfer run is identical to the training runs except for the fact that participants will not receive any neurofeedback signal. The tasks and timing for all 3 rt-fMRI sessions will be identical.

rt-fMRI task: During the rt-fMRI task, the neurofeedback signal will based on participant's activity within either the PCC or amygdala, as per their randomized group assignment. Participants will be told that they will be "regulating brain activity in an area related to emotion." They will not be given any specific strategies with which to regulate brain activity, rather they will be advised to learn individualized strategies that work best for themselves in order to control the feedback signal. The task runs will consist of personalized trauma-associated words chosen by participants that induce emotional responses as well as neutral words. There are 3 different conditions that will occur during the task runs. Prior to each condition, participants will receive/read an instruction that will last approximately 2 seconds and indicates which condition will follow. In one third of the trials the condition will be 'regulate', during which participants will attempt to regulate their brain activity while viewing a trauma-associated word. In another one third of trials the condition will be 'view', during which participants will view a trauma-associated word without making any attempt to regulate their brain activity. In the final one third of the trials the condition will be 'neutral', during which participants will view a neutral word and not attempt to regulate brain activity. The order of the conditions within each task run will be counterbalanced. When presented, each word will be displayed for 24 seconds. Words will be presented using specialized fMRI stimulus delivery software (Presentation, Neurobehavioral Systems, Albany, CA, USA). Participants in the sham-control arm (N=20), will receive a fake neurofeedback signal (i.e., from a successful participant in one of the experimental arms, thereby controlling for motivational effects). Otherwise, the rt-fMRI task and all instructions provided will be identical for participants in the sham-control arm.

Neurofeedback task: During the presentation of words in the fMRI scanner, participants will be able to view a visual feedback display in the form of a thermometer-like bar graph. The number of bars displayed will reflect the amplitude increase of the fMRI signal in the region-of-interest (PCC or amygdala) relative to a baseline period. Feedback will occur every 2 seconds as represented by the number of changing bars. During the 'regulate' condition, participants will be asked to decrease the bars on the thermometer. During the 'view' and 'neutral' conditions, participants will be asked not to try to change the bars on the thermometer. Participants will not be given any specific strategies/guidance regarding how to regulate brain activity.

Qualitative interview: After completion of each fMRI scanning session, participants will complete a semi-structured qualitative interview with the investigator, outside of the scanner. The participants will be asked a number of questions regarding the cognitive strategies they employed to complete the task and their perceived efficacy of the various strategies used. As well, participants will be asked a number of questions relating to their subjective experiences (i.e., motivation, valence, frustration, mind-wandering, etc.) during neurofeedback training. The qualitative interviews will be recorded (via an audio recorder) and transcribed using a third-party transcription service. Any identifying information (i.e., participant name, affiliations, etc.) will be removed from the transcript so it is not possible to identify them from the interview. Transcripts from all participants will be 'pooled together' to analyze common themes across experiences.

(4) Actigraphy devices: Participants will wear a GENEActiv (Activinsights) actigraphy device throughout the duration of the study. The purpose of actigraphy measurements is to monitor participant biological (sleep) rhythms and physical activity. The GENEActive actigraphy device will be worn on the wrist and will collect continuous data at 30Hz.

Connect with a study center

  • Lawson Health Research Institute

    London, Ontario N6C 2R5
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.